Roughly 45% of patients with advanced melanoma develop primary resistance to anti-PD-1 therapy, and until now that population had a sparse menu of formally approved options built specifically for that failure mode. The FDA’s accelerated approval of Tudriqev (vusolimogene oderparepvec-wtpg) on August 6, 2026, changes the calculus, if modestly: in a 140-patient single-arm trial, 24% of evaluable patients achieved an objective response, with a median response duration of 14.1 months. That is not a dominant efficacy signal. But in a refractory setting where durable responses are rare, it is a clinically credible one.
The mechanism is what makes this approval strategically distinct from its predecessor in the oncolytic space. Imlygic (talimogene laherparepvec), the first FDA-approved oncolytic viral therapy, earned its approval in 2015 as a monotherapy for melanoma. Tudriqev is designed explicitly as a combination partner: it is given intratumorally every two weeks for eight doses, with intravenous nivolumab added at week three. The hypothesis is that oncolytic viral lysis of tumor cells can re-sensitize a cold or resistant tumor to checkpoint blockade, essentially attempting to reverse the evasion mechanisms that made prior anti-PD-1 therapy fail. That mechanistic logic is why combining it with nivolumab, itself an anti-PD-1 agent, is not contradictory. It is the whole point.
The trial design carries real interpretive weight here. With 91 evaluable patients out of 140 enrolled and no control arm, the FDA relied on objective response rate and duration of response as surrogate endpoints under accelerated approval, which means confirmatory trials are required. Replimune now bears the burden of verifying clinical benefit in post-approval studies, and the 24% ORR, while meaningful in context, sets a performance bar that randomized data will need to defend or exceed. The safety profile is manageable but demands patient counseling: risks include inadvertent herpes transmission to close contacts and potential herpes reactivation, a consequence of the modified HSV-1 vector that oncology teams will need to communicate clearly.
The single number most worth tracking as Tudriqev moves into practice is the confirmatory trial’s progression-free or overall survival endpoint. Accelerated approval based on response rate has a conversion problem historically, and the size of the anti-PD-1 refractory melanoma population is large enough to matter commercially. If randomized data show a survival benefit, this approval transforms from a niche salvage option into a legitimate second-line anchor. If it does not, the 14-month median response duration becomes a footnote.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
